# EDGAR Filing Document

**Accession Number:** 0002079109
**File Stem:** 0001829126-26-001296
**Filing Date:** 2026-2
**Character Count:** 4556
**Document Hash:** 76e012271366cd6d170f3d1c853da90d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001829126-26-001296.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001829126-26-001296

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260212

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veraxa Biotech Holding AG
- **CENTRAL INDEX KEY:** 0002079109
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001
- **BUSINESS PHONE:** 41443858450

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** TALACKER 35
- **CITY:** ZURICH
- **PROVINCE COUNTRY:** V8
- **ZIP:** 8001

---

| | | |
|:---|:---|:---|
| NEW YORK<br> LONDON<br> SINGAPORE<br> PHILADELPHIA<br> CHICAGO<br> WASHINGTON, DC<br> SAN FRANCISCO<br> SILICON VALLEY<br> SAN DIEGO<br> LOS ANGELES<br> BOSTON<br> HOUSTON<br> DALLAS<br> FORT WORTH<br> AUSTIN | ![](corresp_001.jpg)<br>*FIRM and AFFILIATE OFFICES*<br>ANDY TUCKER<br> PARTNER<br> DIRECT DIAL: +1 202 776 5248<br> PERSONAL FAX: +1 202 330 5313<br> *E-MAIL:* ATucker@duanemorris.com<br>*www.duanemorris.com* | HANOI HO<br> CHI MINH CITY<br> SHANGHAI<br> ATLANTA<br> BALTIMORE<br> WILMINGTON<br> MIAMI<br> BOCA RATON<br> PITTSBURGH<br> NORTH JERSEY<br> LAS VEGAS<br> SOUTH JERSEY<br> SYDNEY<br> MYANMAR<br>ALLIANCES IN MEXICO |

---

February 12, 2026

Ms. Tara Harkins

Mr. Kevin Vaughn

Mr. Tyler Howes

Mr. Chris Edwards

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549-3628

---

| | |
|:---|:---|
| **Re:** | **Veraxa Biotech Holding AG** |

---

**Registration Statement on Form F-4**

**Amendment No. 4 to Registration Statement on Form F-4**

**Filed February 3, 2026**

**File No. 333-289108**

Ladies and Gentleman:

On behalf of our client, Veraxa Biotech Holding AG, a company limited by shares organized under the Laws of Switzerland (the "**Company**"), we are hereby submitting to the staff (the "**Staff**") of the Securities and Exchange Commission (the "**Commission**") this letter setting forth the Company's responses to the comments contained in the Staff's letter dated February 11, 2026 (the "**Comment Letter**") on the Company's Amendment No. 4 to the Registration Statement on Form F-4 filed on February 3, 2026 (the "**Registration Statement**") relating to the proposed business combination involving the Company and Voyager Acquisition Corp., a Cayman Islands exempted company (the "**SPAC**").

<u>Duane Morris LLP</u>   <br> 901 New York Avenue NW, Suite 700 East<br>Washington, D.C. 20001-479 Phone: +1 202 776 7800 Fax: +1 202 776 7801

---

| | |
|:---|:---|
| February 12, 2026<br>Page 2 | ![](corresp_001.jpg) |

---

Concurrently with the submission of this letter, the Company is filing Amendment No. 5 to its registration statement on Form F-4 (the "**Amended Registration Statement**") and certain exhibits via EDGAR with the Commission.

For ease of reference, the headings and numbers of the Company's responses set forth below correspond to the headings and numbers in the Comment Letter, and we have set forth below the text of the Staff's comment prior to each of the Company's responses in the same order as presented in the Comment Letter.

<u>Amendment 4 to Form F-4 filed on February 3, 2026</u>

<u>Risk Factors, page 79</u>

**1.** **We note your disclosure relating to the High Trail Financing Agreement and the Lincoln Park Financing Agreement. Please include risk factor disclosure relating to the fact that the notes are secured by all of your assets and the potential dilution that may result from the equity purchase facility.** 

The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosures on pages 58 and 152 of the Registration Statement in response to the Staff's comment.

We hope that the foregoing has been responsive to the Staff's comments. If you have any questions related to this letter, please direct any such requests or questions to Andy M. Tucker of Duane Morris LLP at (202) 776-5248 or ATucker@duanemorris.com.

---

| |
|:---|
| Sincerely, |
| /s/ Christoph Antz |
| Christoph Antz |

---

*cc*:

Andrew Tucker, Esq.

Michael J. Blankenship, Esq.